From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?

Detalles Bibliográficos
Autores principales: Deng, Haiyi, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107757/
https://www.ncbi.nlm.nih.gov/pubmed/34012802
http://dx.doi.org/10.21037/tlcr-21-179
_version_ 1783690007482990592
author Deng, Haiyi
Zhou, Chengzhi
author_facet Deng, Haiyi
Zhou, Chengzhi
author_sort Deng, Haiyi
collection PubMed
description
format Online
Article
Text
id pubmed-8107757
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-81077572021-05-18 From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform? Deng, Haiyi Zhou, Chengzhi Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2021-04 /pmc/articles/PMC8107757/ /pubmed/34012802 http://dx.doi.org/10.21037/tlcr-21-179 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Deng, Haiyi
Zhou, Chengzhi
From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
title From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
title_full From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
title_fullStr From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
title_full_unstemmed From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
title_short From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
title_sort from checkmate 227 to checkmate 9la: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107757/
https://www.ncbi.nlm.nih.gov/pubmed/34012802
http://dx.doi.org/10.21037/tlcr-21-179
work_keys_str_mv AT denghaiyi fromcheckmate227tocheckmate9larethinkingthestatusofchemotherapyintheimmunotherapyerachemofreeorchemoreform
AT zhouchengzhi fromcheckmate227tocheckmate9larethinkingthestatusofchemotherapyintheimmunotherapyerachemofreeorchemoreform

Ejemplares similares